Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events [4]

Lancet

Volumn 350, Issue 9084, 1997, Pages 1075-1076

  Byington, R P ^a   Craven, T E ^a   Furberg, C D ^a   Pahor, M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; ISRADIPINE;

ADULT; CARDIOVASCULAR DISEASE; DISEASE PREDISPOSITION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK; STATISTICAL ANALYSIS;

EID: 0030801765     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)70455-4     Document Type: Article

References (3)

1. 2+ channel blockers in the membrane lipid bilayer Mol Pharmacol 41 1992 315 321
2. + transport in diabetes mellitus Diabetes 39 1990 850 854
3. Borhani NO Mercuri M Borhani PA Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled study JAMA 276 1996 785 791